NCT03416855 - A Regulatory Post Marketing Surveillance (rPMS) Study of Ryzodeg® FlexTouch® (Insulin Degludec /Insulin Aspart) to Evaluate Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice in Korea | Biotech Hunter

Enrollment

768

Participants

Timeline

Start Date

January 31, 2018

Primary Completion Date

May 19, 2020

Study Completion Date

May 19, 2020

Conditions

DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2

Interventions

DRUG

Insulin degludec /insulin aspart

Commercially available Insulin degludec /insulin aspart (Ryzodeg® FlexTouch®) according to routine clinical practice at the discretion of the treating physician.

Trial Locations (27)

10475

Novo Nordisk Investigational Site, Gyeonggi-do

14068

Novo Nordisk Investigational Site, Gyeonggi-do

14584

Novo Nordisk Investigational Site, Gyeonggi-do

14754

Novo Nordisk Investigational Site, Gyeonggi-do

16247

Novo Nordisk Investigational Site, Suwon-si, Gyeonggi-do

16499

Novo Nordisk Investigational Site, Suwon

22332

Novo Nordisk Investigational Site, Incheon

26426

Novo Nordisk Investigational Site, Gangwon-do

35015

Novo Nordisk Investigational Site, Daejeon

42601

Novo Nordisk Investigational Site, Daegu

47392

Novo Nordisk Investigational Site, Busan

48108

Novo Nordisk Investigational Site, Busan

48575

Novo Nordisk Investigational Site, Busan

49267

Novo Nordisk Investigational Site, Busan

54987

Novo Nordisk Investigational Site, Jeonju

330-721

Novo Nordisk Investigational Site, Daejeon

361-711

Novo Nordisk Investigational Site, Daejeon

410-719

Novo Nordisk Investigational Site, Goyang

561-712

Novo Nordisk Investigational Site, Jeonju